Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CURLF NASDAQ:DNLI NASDAQ:NAMS NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCURLFCuraleaf$1.00-0.6%$0.88$0.68▼$4.43$670.19M0.62562,397 shs286,064 shsDNLIDenali Therapeutics$14.00-3.6%$14.24$10.57▼$33.33$2.03B1.331.15 million shs1.31 million shsNAMSNewAmsterdam Pharma$22.20+1.0%$19.35$14.06▼$27.29$2.49B-0.03746,919 shs951,534 shsVCELVericel$35.34-2.5%$41.54$35.18▼$63.00$1.78B1.32427,426 shs545,056 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCURLFCuraleaf0.00%-13.04%+21.36%+2.04%-76.69%DNLIDenali Therapeutics0.00%-3.58%-0.64%+9.89%-39.16%NAMSNewAmsterdam Pharma0.00%+3.06%+21.98%+35.86%+18.02%VCELVericel0.00%-11.50%-15.41%-14.29%-31.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCURLFCuraleaf2.176 of 5 stars3.52.00.00.01.90.01.3DNLIDenali Therapeutics4.6067 of 5 stars4.51.00.04.73.43.30.0NAMSNewAmsterdam Pharma3.6068 of 5 stars4.42.00.00.01.95.00.0VCELVericel3.7757 of 5 stars3.55.00.00.03.90.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCURLFCuraleaf 3.00Buy$6.25525.00% UpsideDNLIDenali Therapeutics 3.06Buy$33.71140.82% UpsideNAMSNewAmsterdam Pharma 2.89Moderate Buy$41.3086.04% UpsideVCELVericel 3.00Buy$61.1473.01% UpsideCurrent Analyst Ratings BreakdownLatest CURLF, VCEL, NAMS, and DNLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025NAMSNewAmsterdam PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$27.006/17/2025NAMSNewAmsterdam PharmaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.006/12/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.006/10/2025NAMSNewAmsterdam PharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$44.006/4/2025NAMSNewAmsterdam PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/19/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.005/8/2025DNLIDenali TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.005/8/2025NAMSNewAmsterdam PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $40.005/7/2025DNLIDenali TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCURLFCuraleaf$1.34B0.50$0.20 per share4.92$1.51 per share0.66DNLIDenali Therapeutics$330.53M6.15N/AN/A$8.53 per share1.64NAMSNewAmsterdam Pharma$45.56M54.71N/AN/A$8.20 per share2.71VCELVericel$237.22M7.50$0.31 per share113.09$5.92 per share5.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCURLFCuraleaf-$215.42M-$0.31N/AN/AN/A-17.37%-14.12%-4.40%N/ADNLIDenali Therapeutics-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)NAMSNewAmsterdam Pharma-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)VCELVericel$10.36M$0.031,178.3980.32N/A1.25%1.09%0.73%7/31/2025 (Estimated)Latest CURLF, VCEL, NAMS, and DNLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025DNLIDenali Therapeutics-$0.73N/AN/AN/AN/AN/A8/6/2025Q2 2025NAMSNewAmsterdam Pharma-$0.52N/AN/AN/A$1.44 millionN/A7/31/2025Q2 2025VCELVericel-$0.04N/AN/AN/A$64.61 millionN/A5/8/2025Q1 2025CURLFCuraleaf-$0.07-$0.07N/A-$0.08N/AN/A5/8/2025Q1 2025NAMSNewAmsterdam Pharma-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 million5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCURLFCuraleafN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCURLFCuraleaf1.081.410.70DNLIDenali TherapeuticsN/A9.569.56NAMSNewAmsterdam PharmaN/A19.9819.98VCELVericelN/A5.014.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCURLFCuraleaf0.03%DNLIDenali Therapeutics92.92%NAMSNewAmsterdam Pharma89.89%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipCURLFCuraleafN/ADNLIDenali Therapeutics12.50%NAMSNewAmsterdam Pharma20.84%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCURLFCuraleaf5,519670.19 millionN/ANot OptionableDNLIDenali Therapeutics430145.28 million127.12 millionOptionableNAMSNewAmsterdam Pharma4112.27 million88.87 millionOptionableVCELVericel30050.34 million47.73 millionOptionableCURLF, VCEL, NAMS, and DNLI HeadlinesRecent News About These CompaniesSegall Bryant & Hamill LLC Cuts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)July 19 at 6:33 AM | marketbeat.comVericel to Report Second-Quarter 2025 Financial Results on July 31, 2025July 17 at 8:30 AM | globenewswire.comVericel Corporation (NASDAQ:VCEL) Shares Bought by Kornitzer Capital Management Inc. KSJuly 17 at 6:29 AM | marketbeat.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?July 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 4.8% - What's Next?July 15, 2025 | marketbeat.comNew York State Common Retirement Fund Increases Position in Vericel Corporation (NASDAQ:VCEL)July 15, 2025 | marketbeat.comTimesSquare Capital Management LLC Increases Stake in Vericel Corporation (NASDAQ:VCEL)July 14, 2025 | marketbeat.comPrincipal Financial Group Inc. Buys 7,222 Shares of Vericel Corporation (NASDAQ:VCEL)July 14, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)July 4, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from BrokeragesJuly 2, 2025 | marketbeat.comLisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)June 29, 2025 | marketbeat.comIf EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An OpportunityJune 20, 2025 | finance.yahoo.comVericel Corporation: Moving From Sell To NeutralJune 12, 2025 | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11, 2025 | morningstar.comMVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10, 2025 | globenewswire.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 16, 2025 | investing.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comAVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comVericel Corporation 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCURLF, VCEL, NAMS, and DNLI Company DescriptionsCuraleaf OTCMKTS:CURLF$1.00 -0.01 (-0.60%) As of 07/18/2025 03:57 PM EasternCuraleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.Denali Therapeutics NASDAQ:DNLI$14.00 -0.53 (-3.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.00 -0.01 (-0.04%) As of 07/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.NewAmsterdam Pharma NASDAQ:NAMS$22.20 +0.22 (+1.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$22.20 +0.00 (+0.02%) As of 07/18/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Vericel NASDAQ:VCEL$35.34 -0.92 (-2.54%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$36.68 +1.34 (+3.79%) As of 07/18/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
